Skip to main content

Checking the Hippo in Sarcomatoid Renal Cell Carcinoma with Immunotherapy.

Publication ,  Journal Article
Hwang, JK; Agarwal, N; Brugarolas, J; Zhang, T
Published in: Clin Cancer Res
January 1, 2021

Subset analysis of patients with sarcomatoid renal cell carcinoma (sRCC) included in the CheckMate 214 trial of ipilimumab-nivolumab versus sunitinib showed improved outcomes in sRCC with ipilimumab-nivolumab. The use of checkpoint inhibitor-based regimens in sRCC, for which therapeutic options were once limited, is further supported by additional clinical trials.See related article by Tannir et al., p. 78.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Cancer Res

DOI

EISSN

1557-3265

Publication Date

January 1, 2021

Volume

27

Issue

1

Start / End Page

5 / 7

Location

United States

Related Subject Headings

  • Sunitinib
  • Protein Serine-Threonine Kinases
  • Oncology & Carcinogenesis
  • Nivolumab
  • Kidney Neoplasms
  • Ipilimumab
  • Immunotherapy
  • Humans
  • Hippo Signaling Pathway
  • Carcinoma, Renal Cell
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hwang, J. K., Agarwal, N., Brugarolas, J., & Zhang, T. (2021). Checking the Hippo in Sarcomatoid Renal Cell Carcinoma with Immunotherapy. Clin Cancer Res, 27(1), 5–7. https://doi.org/10.1158/1078-0432.CCR-20-3506
Hwang, Joyce K., Neeraj Agarwal, James Brugarolas, and Tian Zhang. “Checking the Hippo in Sarcomatoid Renal Cell Carcinoma with Immunotherapy.Clin Cancer Res 27, no. 1 (January 1, 2021): 5–7. https://doi.org/10.1158/1078-0432.CCR-20-3506.
Hwang JK, Agarwal N, Brugarolas J, Zhang T. Checking the Hippo in Sarcomatoid Renal Cell Carcinoma with Immunotherapy. Clin Cancer Res. 2021 Jan 1;27(1):5–7.
Hwang, Joyce K., et al. “Checking the Hippo in Sarcomatoid Renal Cell Carcinoma with Immunotherapy.Clin Cancer Res, vol. 27, no. 1, Jan. 2021, pp. 5–7. Pubmed, doi:10.1158/1078-0432.CCR-20-3506.
Hwang JK, Agarwal N, Brugarolas J, Zhang T. Checking the Hippo in Sarcomatoid Renal Cell Carcinoma with Immunotherapy. Clin Cancer Res. 2021 Jan 1;27(1):5–7.

Published In

Clin Cancer Res

DOI

EISSN

1557-3265

Publication Date

January 1, 2021

Volume

27

Issue

1

Start / End Page

5 / 7

Location

United States

Related Subject Headings

  • Sunitinib
  • Protein Serine-Threonine Kinases
  • Oncology & Carcinogenesis
  • Nivolumab
  • Kidney Neoplasms
  • Ipilimumab
  • Immunotherapy
  • Humans
  • Hippo Signaling Pathway
  • Carcinoma, Renal Cell